Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Depression

New study claims antidepressant withdrawal is less common than thought. But there’s a big problem

by Mark Horowitz and Joanna Moncrieff
June 9, 2024
in Depression, Psychopharmacology
[Adobe Stock]

[Adobe Stock]

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

A new review of research about antidepressant withdrawal has confirmed it does exist, but also reports that it’s less common and severe than previously found.

These findings feed into a growing debate about how common and severe withdrawal effects are. But we argue the researchers probably underestimate the incidence in long-term users who are most at risk of withdrawal effects.

One of the main limitations of this review is that it involved mostly short-term antidepressant users and therefore underestimates how common these symptoms are in people who take the drugs long-term. This is a growing group of people – and research shows they’re most at risk of experiencing withdrawal.

The systematic review looked at 79 studies in total. Based on their analysis, the researchers reported that one in three people who stopped antidepressants experienced withdrawal effects. The authors also found that one in six people who’d been taking a placebo antidepressant reported experiencing withdrawal effects after stopping (often called the “nocebo” effect).

Taking this data into account, they concluded that about one in six people experienced withdrawal effects due to the antidepressants. The researchers also reported that only 3% of people demonstrated severe withdrawal effects, and they questioned whether some of these withdrawal effects were actually a return of people’s underlying mental health problem.

Confirmation of antidepressant withdrawal will be welcomed by many people. While UK prescribing guidelines used to state withdrawal effects are typically mild and brief in most patients, tens of thousands of people have come forward in petitions, newspaper articles and on social media, reporting to have experienced severe withdrawal symptoms. Many describe problems including new-onset panic attacks, obsessive thinking, akathisia (a state of restlessness, agitation and terror) and profound risk of suicide.

In 2019, the first systematic review on antidepressant withdrawal found the picture was more congruent with what patients were reporting. The study found half of patients prescribed antidepressants experienced withdrawal effects – and half of these people reported severe symptoms.

Study limitations

The latest findings add to this picture, and it useful to have it confirmed that antidepressant withdrawal does occur and is not uncommon. But there are several reasons why they are not as reassuring as they seem.

First, the majority of studies included in the review were short-term studies conducted by drug manufacturers who have no incentive to detect withdrawal symptoms.

What’s more, many of the studies were not designed to examine withdrawal and did so only incidentally or did not thoroughly assess withdrawal symptoms. This probably underestimated the incidence of withdrawal effects.

The average time people were on antidepressants in the studies included in the review was only 25 weeks. This is a far cry from how long many people use these drugs in clinical practice.

Half of patients in the UK who are on antidepressants have used them for more than two years – with 2 million people on them for than five years. In the US, half of people taking antidepressants are on them for more than five years.

We know that the longer people use antidepressants the more common and severe their withdrawal symptoms are when stopping. The authors of the paper reported that they found no relationship between how long people were taking antidepressants and risk of withdrawal effects but this is probably because they only looked at short-term studies, with very few studies lasting for more than a year.

One survey found that one in three people who had used antidepressants for three to six months reported withdrawal effects (similar to the results of the current meta-analysis) – with one-fifth reporting moderate or severe withdrawal effects.

For those who used antidepressants for more than three years, two-thirds reported withdrawal effects – and half reported these were moderate or severe. It’s therefore likely the new review underestimates how common and severe withdrawal symptoms are for long-term antidepressant users.

The other major limitation of this review is that it assumed withdrawal effects from placebos and antidepressants were equivalent. However, symptoms were probably less intense in the placebo group.

In the few studies included in the review that did look at severity, people stopping antidepressants were seven times more likely to experience severe withdrawal effects as those stopping a placebo. Comparing the rates from these two groups is like comparing apples and oranges.

The review’s authors also suggest that some of the reported withdrawal symptoms (such as emotional disturbance) may be a recurrence of the underlying mental health problem mistakenly classified as withdrawal. But it may be just as likely that some withdrawal symptoms could have been mis-classified as recurrence which may have meant they underestimated withdrawal effects.

And since depression is a fluctuating condition that comes and goes over time, it would be improbable for so many patients to relapse immediately after stopping antidepressants.

It’s clear we need better quality research conducted in long-term users to more accurately know the risks. It’s concerning that after decades of antidepressants being on the market so little attention has been paid to this major public health issue.

The risks of severe and long-lasting withdrawal effects should be taken into account when considering an antidepressant. These drugs should also be stopped more carefully than is normally done because of these risks.The Conversation

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

TweetSendScanShareSendPin1ShareShareShareShareShare

RELATED

New research links postnatal depression to a disrupted oxytocin response during breastfeeding
Depression

New research links postnatal depression to a disrupted oxytocin response during breastfeeding

May 15, 2025

A new study finds that postnatal depression may impair the body’s hormonal response to breastfeeding. While oxytocin nasal spray boosted breast milk levels in healthy mothers, the same effect was not seen in those experiencing depressive symptoms after childbirth.

Read moreDetails
Neuroscience research sheds light on ketamine’s strange effect on our sense of touch
Ketamine

Ketamine’s antidepressant effects appear unrelated to stress hormones, study finds

May 15, 2025

New research suggests that hormones linked to the body’s stress response do not influence how people with treatment-resistant depression respond to ketamine. However, lower hormone levels were associated with longer depressive episodes, pointing to possible biomarkers for depression duration.

Read moreDetails
Psychedelic experiences linked to long-term improvements in psychological flexibility, study finds
Psychedelic Drugs

Psychedelic experiences linked to long-term improvements in psychological flexibility, study finds

May 15, 2025

French researchers surveyed hundreds of psychedelic users and found that mystical experiences predicted lasting improvements in psychological flexibility. These findings shed light on how psychedelics might promote emotional resilience by disrupting rigid thinking patterns and encouraging openness to experience.

Read moreDetails
Scientists reveal how DMT alters brain activity and consciousness by lowering control energy
Neuroimaging

Scientists reveal how DMT alters brain activity and consciousness by lowering control energy

May 14, 2025

A new study used fMRI and EEG to show that DMT reduces the energy needed for the brain to shift between activity states. These changes tracked with increased signal complexity and were strongest in regions rich in serotonin 2a receptors.

Read moreDetails
Women who drink alcohol have an increased risk of sexual dysfunction
ADHD

Alcohol use has particularly negative impact on individuals with ADHD

May 13, 2025

A new study published in the Journal of Psychiatric Research finds that alcohol harms quality of life more severely in individuals with ADHD. Emotional dysregulation and impulsivity appear to intensify the negative effects of alcohol in this vulnerable group.

Read moreDetails
Psychedelics linked to religious disaffiliation—but not spiritual change—in large-scale study
Psychedelic Drugs

Psychedelics linked to religious disaffiliation—but not spiritual change—in large-scale study

May 13, 2025

Psychedelics are often described as spiritual tools—but do they change people’s religious beliefs? A large new study found that while psychedelic use was associated with religious disaffiliation, it did not cause lasting changes in religiosity or spirituality over time.

Read moreDetails
Stress-induced “fixated” eating patterns linked to dopamine disruption, study finds
Depression

New research links antidepressant effects of escitalopram to endocannabinoid system changes

May 12, 2025

In a rodent model of childhood adversity, escitalopram treatment during adolescence reduced signs of emotional distress. The study also found gene-level changes in the endocannabinoid system, pointing to a possible biological mechanism for the drug’s effectiveness.

Read moreDetails
Antidepressants may diminish psilocybin’s effects even after discontinuation
Depression

A single dose of psilocybin might help reduce symptoms in treatment-resistant depression

May 12, 2025

A new open-label study suggests that a single dose of psilocybin, combined with psychological support, may reduce symptoms in people with severe treatment-resistant depression. Improvements were sustained for up to 12 weeks, although effects were weaker in those with PTSD.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Caffeine and Alzheimer’s disease: Moderate intake may slow cognitive decline

New research links postnatal depression to a disrupted oxytocin response during breastfeeding

Ketamine’s antidepressant effects appear unrelated to stress hormones, study finds

Surprisingly strong link found between neighborhood greenness and police shootings

Psychedelic experiences linked to long-term improvements in psychological flexibility, study finds

ADHD symptoms appear to influence women’s orgasms

Biographical details influence how attractive we find faces and change how our brains respond, study finds

Neuroscientists discover music’s hidden power to reshape memory

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy